|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Integrating the Use of Prostate Genomic Classifiers into Clinical Practice - A Clinical Pathway Approach
|
Katie Murray, DO, MS, FACS AND Anne Lizardi-Calvaresi, DNP, RNFA
Katie Murray and Anne Lizardi-Calvaresi discuss a clinical pathway approach for using the Decipher prostate cancer genomic classifier.
|
|
|
|
|
|
|
|
|
|
|
|
Rationale for the Use of Decipher RP Genomic Classifier to Inform Treatment
|
Ashley Ross, MD, Ph.D.
Alicia Morgans and Ashley Ross discuss Decipher RP genomic classifier for prostatectomy specimens, and how to integrate these tests into clinical practice.
|
|
|
|
|
|
|
|
|
|
|
|
The Use of Genomics in Unfavorable Intermediate-Risk Prostate Cancer
|
|
David Morris, MD, FACS
|
| David Morris joins Ashley Ross in a conversation on genomics in prostate cancer specifically, in the unfavorable intermediate-risk patient.
|
|
|
|
|
|
|
|
|
|
|
|
|
Genomic and Clinical Markers in nmCRPC
|
|
Joaquin Mateo, MD, Ph.D.
|
| Joaquin Mateo presents genomic and clinical markers in non-metastatic castrate-resistant prostate cancer (nmCRPC).
|
|
|
|
|
|
|
|
|
|
|
|
| Genomic and Clinical Markers in nmCRPC
|
| Joaquin Mateo, MD, Ph.D.
|
| Joaquin Mateo discusses genomic and clinical markers in this disease space. We need to understand biological differences between tumors that evolve towards nmCRPC versus those that evolve towards mCRPC up front. Liquid biopsy could provide an additional measure of tumor burden, including more accurate disease evaluation, and compliment imaging for monitoring response and disease progression.
|
|
|
|
|
|
|
|
|
|
|
| Prostate Cancer: Genetics and Markers
|
| Dipen J. Parekh, MD
|
| In this presentation, Dipen Parekh discusses genetics and markers for patients with prostate cancer. Dr. Parekh presents a case of a 67-year-old male with a PSA of 5.7 ng/mL, past medical history of hypertension and diabetes, with a SHIM of 25 and a desire to preserve sexual function.
|
|
|
|
|
|
| State-of-the-Art Lecture: Personalized Medicine in the Management of Prostate Cancer Across the Patient Care Continuum
|
| Brian Chapin, MD
|
| Brian Chapin discusses personalized medicine in the management of prostate cancer across the patient care continuum. Dr. Chapin notes that progress is being made in the personalized care of prostate cancer patients. However It is important to delineate between predictive versus prognostic markers and we need validation of markers to predict a therapeutic benefit.
|
|
|
|
|
|
|
